All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2019-10-23T09:34:15.000Z

Quizartinib refused marketing authorization by EMA CHMP

Featured
Oct 23, 2019
Share:

Bookmark this article

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has refused marketing authorization to quizartinib for the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with a FLT3-internal tandem duplication (ITD).1,2 Having reviewed the data presented, the EMA CHMP felt that despite marginal improvement in overall survival (OS), the study had limitations that did not allow the efficacy of quizartinib to be demonstrated sufficiently for approval. They concluded that the benefits did not outweigh the risks and refused the marketing authorization.1

In May 2019, quizartinib was also rejected by the United States (US) Food & Drug Administration (FDA). The FDA Oncologic Drug Advisory Committee voted 8–3 against approval of the new drug application (NDA) and raised questions regarding the generalizability and credibility of the data.3 Quizartinib had previously been granted orphan drug designation by the EMA and breakthrough therapy designation by the FDA.4,5

Clinical Trials6

The results from the QuANTUM-R trial, which assessed the value of quizartinib compared to investigator’s choice of salvage chemotherapy, were recently published in Lancet Oncology.

Given as quizartinib vs salvage chemotherapy

  • Median OS: 6.2 vs 4.7 months
  • Estimated 12-month survival: 27% vs 20%
  • Hazard ratio for progression or death: 0.76, 95% CI: 0.58–0.92, p= 0.02
  • Treatment-emergent deaths: 33% vs 17%

This study concluded quizartinib monotherapy conferred a survival benefit compared to salvage chemotherapy, with a manageable safety profile for patients with FLT3-ITD R/R AML.

The ongoing QuANTUM-First study (NCT02668653) is evaluating quizartinib plus standard chemotherapy followed by quizartinib monotherapy will benefit patients with newly diagnosed AML.

Expert Opinion

  1. European Medicines Agency. Refusal of the marketing authorisation for Vanflyta (quizartinib). https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-vanflyta-quizartinib_en.pdf [Accessed 2019 Oct 22]
  2. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019. [Accessed 2019 Oct 22]
  3. OncLive. FDA Panel Votes Against Quizartinib for AML. https://www.onclive.com/web-exclusives/fda-panel-votes-against-quizartinib-approval-for-aml [Accessed 2019 Oct 22]
  4. European Medicines Agency. EU/3/09/622. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309622-0. [Accessed 2019 Oct 22]
  5. BioSpace: FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML. 2018 Aug 01. https://www.biospace.com/article/releases/fda-grants-breakthrough-therapy-designation-to-daiichi-sankyo-s-flt3-inhibitor-quizartinib-for-relapsed-refractory-flt3-itd-aml/ [Accessed 2019 Oct 22]
  6. Cortes J.E. et al., Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Onc. 2019 Jun 04. DOI: 10.1016/ S1470-2045(19)30150-0

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox